| Literature DB >> 31213868 |
Brandon H Mai1, Liang-Jun Yan1.
Abstract
The increased consumption of fructose in the average diet through sweeteners such as high-fructose corn syrup (HFCS) and sucrose has resulted in negative outcomes in society through producing a considerable economic and medical burden on our healthcare system. Ingestion of fructose chronically has contributed to multiple health consequences, such as insulin resistance, obesity, liver disorders, and diabetes. Fructose metabolism starts with fructose phosphorylation by fructose kinase in the liver, and this process is not feedback regulated. Therefore, ingestion of high fructose can deplete ATP, increase uric acid production, and increase nucleotide turnover. This review focuses the discussion on the hepatic manifestations of high fructose-implicated liver metabolic disorders such as insulin resistance, obesity due to enhanced lipogenesis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and type 2 diabetes. The detrimental effects of high fructose on the liver, contributed potentially by microbiome and leptin, were also discussed. The authors believe that, together with diet management, further studies focusing on disrupting or blocking fructose metabolism in the liver may help with designing novel strategies for prevention and treatment of fructose-induced chronic liver metabolic diseases.Entities:
Keywords: fructose; liver; metabolic syndrome; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis
Year: 2019 PMID: 31213868 PMCID: PMC6549781 DOI: 10.2147/DMSO.S198968
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Figure 1Fructose metabolism via fructokinase. This pathway is uncontrolled and can deplete ATP and is involved in uric acid production (as highlighted in the figure). Consequently, the fall in ATP and increase in uric acid can cause oxidative stress, inhibition of protein synthesis, and mitochondrial dysfunction, which can further induce obesity, insulin resistance, and fatty liver that eventually manifest in global metabolic syndrome.